Flaig: It has been a remarkable 10 years for bladder cancer. If you think back to 10 or 15 years ago, we had no new ...

As new therapies emerge, particularly for non-muscle invasive disease, clinicians and patients are faced with increasingly ...

A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows.

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that ANKTIVA (R) (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia. Initial ...

ImmunityBio IBRX enters 2026 with a commercial story that is unusually concentrated. Anktiva is the company’s first marketed ...

Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus ...

Using multiparametric MRI (mpMRI) before surgery reduced time to correct treatment by 45 days for patients with muscle invasive bladder cancer. The imaging procedure was successful for over 92% of ...

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...